Company: FTII
Filing Date: 2025-02-14
Form Type: S-4
Source: 0001493152-25-006997
Chunk: 181

Company: FutureTech II Acquisition Corp.
Filing Date: 2025-02-14
Form: S-4
Chunk 181
---
combines the historical statements of operations of FutureTech, the historical statements of operations of Longevity, the historical statements
of operations of Aegeria and the historical statements of operations of Cerevast on a pro forma basis as if each of the Business Combination
and Other Related Events summarized below had been consummated on January 1, 2023, the beginning of the earliest period presented.

There are two pro forma presentations:

The unaudited
pro forma condensed combined financial information was derived from and should be read in conjunction with the following historical financial
statements and the accompanying notes, which are included elsewhere in this proxy statement/prospectus:

| 80 |

| ● | other information relating to FutureTech, Longevity, Aegeria and Cerevast included in this proxy statement/prospectus,           
 including the Transaction Agreements and the description of certain terms thereof set forth under the section entitled “Proposal 
 No. 1 — The Business Combination Proposal.”                                                                                      |

The unaudited
pro forma condensed combined financial information should also be read together with the sections entitled “FutureTech Management’s
Discussion and Analysis of Financial Condition and Results of Operations,” “Longevity Management’s Discussion and Analysis
of Financial Condition and Results of Operations,” “Aegeria Management’s Discussion and Analysis of Financial Condition
and Results of Operations,” “Cerevast Management’s Discussion and Analysis of Financial Condition and Results of Operations,”
and other financial information included elsewhere in this proxy statement/prospectus.

Description of the Business Combination

Longevity will
acquire the outstanding equity interests in each of Aegeria and Cerevast. Longevity will merge with and into Merger Sub, with Longevity
being the surviving entity and a subsidiary of FutureTech, and existing equity holders of Longevity will convert their equity ownership
into equity ownership in FutureTech (the “Combined Company”). At the Closing, FutureTech will change its name to “Longevity
Biomedical, Inc.”

Other Related Events

Other Related
Events that are contemplated to occur in connection with the Business Combination are summarized below:

| ● | the amendment and restatement of FutureTech’s certificate of incorporation, to occur upon the Effective 
 Time;                                                                                                   |

| ● | the assumption by FutureTech at the Effective Time of all obligations of Longevity under each outstanding 
 Longevity converted stock option and the agreements evidencing the grants thereof;                        |

| ● | the conversion of the Longevity promissory notes. The Longevity prom